Mutual of America Capital Management LLC Sells 7,028 Shares of Pfizer Inc. $PFE

Mutual of America Capital Management LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 1.1% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 651,033 shares of the biopharmaceutical company’s stock after selling 7,028 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Pfizer were worth $15,781,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Pacer Advisors Inc. increased its holdings in Pfizer by 856.8% during the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock valued at $508,164,000 after purchasing an additional 17,957,928 shares during the period. Amundi grew its position in shares of Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock worth $1,265,277,000 after buying an additional 15,758,846 shares during the last quarter. Nuveen LLC purchased a new position in shares of Pfizer during the first quarter valued at approximately $389,861,000. Goldman Sachs Group Inc. raised its holdings in shares of Pfizer by 51.9% during the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock valued at $670,407,000 after acquiring an additional 9,041,990 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Pfizer by 0.9% in the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock worth $13,257,004,000 after acquiring an additional 4,629,976 shares during the period. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on PFE. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Bank of America boosted their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Citigroup raised their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. UBS Group reiterated a “neutral” rating and set a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $28.13.

Pfizer Price Performance

Shares of PFE opened at $24.52 on Friday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $29.36. The firm’s 50-day simple moving average is $24.89 and its two-hundred day simple moving average is $24.11. The stock has a market cap of $139.38 billion, a PE ratio of 13.04, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. During the same period in the previous year, the firm posted $0.60 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.